Your browser doesn't support javascript.
loading
Frailty in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Receiving Curative-Intent Therapy: A Population-Based Study.
Vijenthira, Abi; Mozessohn, Lee; Nagamuthu, Chenthila; Liu, Ning; Blunt, Danielle; Alibhai, Shabbir; Prica, Anca; Cheung, Matthew C.
Afiliación
  • Vijenthira A; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre.
  • Mozessohn L; Department of Medicine, University of Toronto.
  • Nagamuthu C; Department of Medicine, University of Toronto.
  • Liu N; Division of Medical Oncology and Hematology, Sunnybrook Odette Cancer Centre, and.
  • Blunt D; Cancer Research Program, Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada.
  • Alibhai S; Cancer Research Program, Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada.
  • Prica A; Cancer Research Program, Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada.
  • Cheung MC; Division of Hematology, Royal Adelaide Hospital, Adelaide, South Australia, Australia; and.
J Natl Compr Canc Netw ; 20(6): 635-642.e9, 2022 06.
Article en En | MEDLINE | ID: mdl-35714676
BACKGROUND: The objectives of this study were to determine whether frailty is associated with survival in a population-based sample of patients with diffuse large B-cell lymphoma (DLBCL) and to describe the healthcare utilization patterns of frail versus nonfrail patients during treatment. METHODS: A retrospective cohort study was conducted using population-based data in Ontario, Canada. Patients aged ≥66 years diagnosed between 2006 and 2017 with DLBCL or transformed follicular lymphoma who received first-line curative-intent chemoimmunotherapy were included. Frailty was defined using a modified version of a generalizable frailty index developed for use with Ontario administrative data. Cox regression was performed to examine the association between frailty and 1-year mortality. RESULTS: A total of 5,527 patients were included (median age, 75 years [interquartile range, 70-80 years]; 48% female), of whom 2,699 (49%) were classified as frail. Within 1 year of first-line treatment, 32% (n=868) of frail patients had died compared with 20% (n=553) of nonfrail patients (unadjusted hazard ratio, 1.8; 95% CI, 1.6-2.0; P<.0001). Frail patients had higher healthcare utilization during treatment, with most hospitalizations related to infection and/or lymphoma. In multivariable modeling controlling for age, inpatient diagnosis, number of chemoimmunotherapy cycles received, comorbidity burden, and healthcare utilization, frailty remained independently associated with 1-year mortality (adjusted hazard ratio, 1.5; 95% CI, 1.3-1.7; P<.0001). CONCLUSIONS: In a population-based sample of older adult patients with DLBCL receiving front-line curative-intent therapy, half were classified as frail, and their adjusted relative rate of death in the first year after starting treatment was 50% higher than that of nonfrail patients. Frailty seems to be associated with poor treatment tolerance and a higher likelihood of requiring acute hospital-based care.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Linfoma de Células B Grandes Difuso / Fragilidad Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies Límite: Aged / Female / Humans / Male País/Región como asunto: America do norte Idioma: En Revista: J Natl Compr Canc Netw Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Linfoma de Células B Grandes Difuso / Fragilidad Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies Límite: Aged / Female / Humans / Male País/Región como asunto: America do norte Idioma: En Revista: J Natl Compr Canc Netw Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article